BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 7, 2026
Breaking News: Read BioWorld's AACR 2026 coverageSee today's BioWorld Science
Home » HSD17B8 methylation status distinguishes metaplastic breast cancer from phyllodes tumor
To read the full story, subscribe or sign in.
Biomarkers

HSD17B8 methylation status distinguishes metaplastic breast cancer from phyllodes tumor

Feb. 2, 2024
Phyllodes tumors (PTs) are rare, fibroepithelial tumors of the breast that can arise as benign, borderline or malignant. Little is known about the molecular mechanisms behind their occurrence, and it is easy to misdiagnose them as other histologically similar tumors, such as metaplastic breast cancer. It was hypothesized that DNA methylation could be a helper here.
BioWorld Science Biomarkers Cancer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • Regulatory actions for May 5, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing